|Under development for release in 2017
LabKey Biologics will be available for subscription purchase from LabKey Software in 2017. Please contact LabKey
if you'd like to influence product development or learn more.
LabKey and Just Biotherapeutics, Inc.
have signed a multi-year agreement to develop a new software product that helps biotechnology R&D teams produce more effective and affordable biotherapeutics by optimizing development processes.
The new solution will enable preclinical research groups to accelerate lab workflows, automate project tracking, and gain immediate insight into molecules, processes and resources. With data intelligence on hand, teams can focus on developing high-quality therapeutics instead of battling bottlenecks in data entry, integration and analysis.
“LabKey builds software solutions that help research scientists integrate, analyze and share biomedical data, speeding their efforts to treat and cure diseases. We’re thrilled to be working with a team focused on innovation in biotherapeutics,” says Michael Gersch, CEO of LabKey. “We are very impressed with the Just team and their inspiring vision of bringing biologic medicines to global markets. We’re delighted to partner with them on this new product.”
The two companies will design, develop and implement a LabKey Software product for biotherapeutics R&D development based on Just’s specifications and requirements. The product will also be available for other companies to use.
“Today's software solutions aren't geared toward the problems that Just and other companies are working to solve with large molecule development,” says Jim Thomas, CEO of Just. “This partnership and resulting innovative product will make it easier for companies to accelerate the development of biotherapeutics.”